CTA confirms acute Type A aortic dissection, and the operating room is being mobilized. The patient took apixaban four hours ago. The immediate question is not simply whether to reverse the anticoagulant: it is how to reduce bleeding risk without undermining the heparin anticoagulation needed for cardiopulmonary bypass (CPB).
In this illustrative case, the patient is a 58-year-old man with atrial fibrillation and poorly controlled hypertension. His exact apixaban dose, current renal function, interacting medications, and use of antiplatelet drugs still need to be confirmed. Do not fill in those missing details from the medication list alone.
Emergency repair is not elective washout
Acute Type A dissection requires emergency surgical evaluation. Elective instructions to hold apixaban for a set interval do not fit this situation. A brief delay may be considered only if the surgical team judges it safe; waiting for routine drug clearance must not become a reflexive reason to postpone a lifesaving operation.
While surgery is organized, continue appropriate anti-impulse therapy and analgesia. In parallel, establish what anticoagulant effect may remain and make the reversal plan with the cardiac surgeon, cardiac anesthesiologist, perfusion team, and pharmacy or hematology support as available.
Measure residual activity—not the INR
A four-hour interval after a dose does not establish how much apixaban remains, but clinically important activity is plausible. The useful information is the exact last dose and time, renal function, and—if a result can be obtained promptly—an apixaban-calibrated anti-Xa concentration.
| Information or test | How it helps | Common trap |
|---|---|---|
| Exact last dose and time; current renal function; interacting drugs | Helps estimate whether clinically relevant drug may remain | Treating “took it today” as a sufficient medication history |
| Apixaban-calibrated anti-Xa level, if rapidly available | Estimates residual apixaban more directly | Waiting for a delayed result when the operation cannot safely wait |
| PT/INR or aPTT | May help assess other aspects of coagulation | Treating a normal result as proof that apixaban is absent |
Routine clotting tests are not reliable measures of apixaban concentration; a normal PT/INR or aPTT does not exclude a relevant drug level. Some perioperative guidance uses less than 30 ng/mL as a low-residual reference for major surgery. That is not a universal guarantee of hemostasis or a validated all-clear threshold for every CPB case. If a drug-specific result cannot return without delaying necessary repair, communicate the uncertainty rather than waiting on the test.
Choose reversal with the bypass circuit in mind
If clinically important apixaban activity is present or strongly suspected and surgery cannot wait, the team may consider off-label 4-factor prothrombin complex concentrate (4F-PCC) under its local protocol. The decision should account for the level of residual drug when available, the bleeding risk of the operation, any active hemorrhage, and the patient’s thrombotic risk.
4F-PCC is not a drug-binding antidote: it can support thrombin generation and hemostasis, but it does not remove apixaban or make the drug-specific anti-Xa concentration disappear. It also carries thrombotic risk. Do not give it automatically just because the reported last dose was recent, and do not use a subsequent anti-Xa result as though PCC had cleared the drug.
The other important trap is reflexively choosing andexanet alfa because it is associated with factor Xa inhibitor reversal. Before CPB, andexanet can cause acquired heparin resistance: unfractionated heparin may fail to produce the anticoagulation needed to protect the bypass circuit. Current cardiac-surgery consensus advises against its use when CPB heparinization is required. In the United States, commercial sales ended on December 22, 2025; verify local availability rather than assuming it can be obtained. If it has already been administered, alert the perfusion and anesthesia teams immediately so they can plan and monitor anticoagulation together.
Protamine reverses heparin; it does not reverse apixaban. Keeping those two drugs—and their different reversal strategies—separate prevents a deceptively simple but dangerous medication error.
Make the handoff actionable
The receiving team needs more than “on Eliquis.” Give a concise, specific handoff:
- Apixaban indication, dose, and exact time of last dose.
- Current creatinine and renal function, with relevant prior baseline if available; list interacting drugs and any antiplatelet therapy.
- Apixaban-calibrated anti-Xa result and assay type, if obtained, or whether testing was unavailable or would delay surgery.
- Any reversal product given, including dose and time, and the reason for giving it.
- The plan for heparinization and activated clotting time monitoring on bypass, especially if andexanet was already administered.
- A plan to reassess postoperative anticoagulation for atrial fibrillation once surgical hemostasis and the repair permit.
The goal is not for the medical resident to choose a bypass anticoagulation protocol independently. It is to ensure the team has the facts that change that protocol—and that the last dose, uncertainty, and reversal decision are not lost during transfer.
Practical takeaways
- Type A dissection repair is an emergency; routine elective apixaban hold intervals do not determine the surgical clock.
- Confirm dose, last-dose time, renal function, interacting drugs, and concurrent antiplatelet therapy.
- Use a rapidly available apixaban-calibrated anti-Xa level when helpful; normal PT/INR or aPTT does not rule out residual apixaban.
- Consider 4F-PCC only through a team-based, protocol-guided decision when surgery cannot wait and residual activity is clinically important; it does not clear apixaban and may increase thrombosis risk.
- Avoid reflexive andexanet before CPB because heparin resistance can endanger the bypass circuit.
